Serous tumors of low malignant potential of the ovary-molecular pathology: part 2

被引:15
作者
Hauptmann, S [1 ]
Dietel, M [1 ]
机构
[1] Humboldt Univ, Charite Hosp, Inst Pathol, D-10117 Berlin, Germany
关键词
borderline tumors; tumors of low malignant potential; ovary; serous tumors; genetics; hormone receptors; oncogenes; tumor suppressor genes; inflammation; desmoplasia;
D O I
10.1007/s004280100435
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
A progressive development from serous tumors of low malignant potential (SLMP) to bluntly invasive serous carcinoma has been suggested in parallel to the concept of adenoma-carcinoma sequence in colorectal carcinomas. However, recent genetic data enforces a reassessment of the concept that SLMP tumors represent precursor lesions to invasive serous carcinoma. Despite the benign nature of the majority of these tumors, some will behave worse. The identification of those SLMP tumors with an aggressive clinical behavior remains difficult, regardless of a growing body of molecular pathologic investigations. Expression of p53, c-erbB2, as well as the presence of ras mutations are not helpful in this respect. Immunostaining of both MMP-2 and basement membrane components such as collagen type IV, as well as the disintegration of collagen type I at the tumor-host inter-face, may be helpful for the diagnosis of a microinvasive SLMP, but it remains questionable whether this is important for prognosis. The differential diagnosis to frankly invasive carcinoma depends on the detection of destructive stromal invasion. In questionable cases, the loss of N-cadherin would argue for the presence of a carcinoma whereas the coexpression of p21 and MDM2 is rather characteristic for SLMP tumors.
引用
收藏
页码:539 / 551
页数:13
相关论文
共 160 条
  • [1] Estrogen receptor expression is a common feature of ovarian borderline tumors
    AbuJawdeh, GM
    Jacobs, TW
    Niloff, J
    Cannistra, SA
    [J]. GYNECOLOGIC ONCOLOGY, 1996, 60 (02) : 301 - 307
  • [2] MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: Possible implications for the role of desmoplastic fibroblasts
    Afzal, S
    Lalani, EN
    Poulsom, R
    Stubbs, A
    Rowlinson, G
    Sato, H
    Seiki, M
    Stamp, GWH
    [J]. HUMAN PATHOLOGY, 1998, 29 (02) : 155 - 165
  • [3] Auersperg N, 1996, OVARIAN CANCER 4, P3
  • [4] AUTIOHARMAINEN H, 1993, LAB INVEST, V69, P312
  • [5] IMMUNOHISTOCHEMICAL ANALYSIS OF THE P53 ONCOPROTEIN ON PARAFFIN SECTIONS USING A SERIES OF NOVEL MONOCLONAL-ANTIBODIES
    BARTEK, J
    BARTKOVA, J
    LUKAS, J
    STASKOVA, Z
    VOJTESEK, B
    LANE, DP
    [J]. JOURNAL OF PATHOLOGY, 1993, 169 (01) : 27 - 34
  • [6] LOSS OF EPITHELIAL DIFFERENTIATION AND GAIN OF INVASIVENESS CORRELATES WITH TYROSINE PHOSPHORYLATION OF THE E-CADHERIN BETA-CATENIN COMPLEX IN CELLS TRANSFORMED WITH A TEMPERATURE-SENSITIVE V-SRC GENE
    BEHRENS, J
    VAKAET, L
    FRIIS, R
    WINTERHAGER, E
    VANROY, F
    MAREEL, MM
    BIRCHMEIER, W
    [J]. JOURNAL OF CELL BIOLOGY, 1993, 120 (03) : 757 - 766
  • [7] CHROMOSOME-ABERRATIONS IN METASTATIC OVARIAN-CANCER - RELATIONSHIP WITH ABNORMALITIES IN PRIMARY TUMORS
    BELLO, MJ
    REY, JA
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1990, 45 (01) : 50 - 54
  • [8] Ben-Hur H, 2000, EUR J GYNAECOL ONCOL, V21, P141
  • [9] OVEREXPRESSION OF P53 IS NOT A FEATURE OF BENIGN AND EARLY-STAGE BORDERLINE EPITHELIAL OVARIAN-TUMORS
    BERCHUCK, A
    KOHLER, MF
    HOPKINS, MP
    HUMPHREY, PA
    ROBBOY, SJ
    RODRIGUEZ, GC
    SOPER, JT
    CLARKEPEARSON, DL
    BAST, RC
    [J]. GYNECOLOGIC ONCOLOGY, 1994, 52 (02) : 232 - 236
  • [10] BERCI G, 1990, POSTGRAD GEN SURG, V2, P50